September 18: “Reversed & Remanded: The Impact of Recent Appellate Court Rulings on Mass Torts”

Date: Monday, Sept. 18, 2017
Time: 2pm Eastern | 1pm Central | 12pm Mountain | 11am Pacific
Duration: 90 minutes
Format: Broadcast live from the JAMS Resolution Center, New York
CLE: This webinar is eligible for CLE (depending on state and local rules)
Price: Complimentary
Register: Sign up for the program here

“I thought mass tort practice was going to be directed by legislation, but state and federal appellate courts, and the U.S. Supreme Court, have stepped in and mixed things up.” –Judge Marina Corodemus (ret.) 

Judge Corodemus is referring to a spate of rulings this year that are significant to mass tort attorneys everywhere.

In its BNSF Railway Co. v. Tyrrell decision, the Supreme Court held that its general jurisdiction holding in Daimler AG v. Bauman wasn’t limited to only certain types claims. Shortly after that the high court handed down its much-anticipated jurisdiction ruling in Bristol Myers v. Superior Court, a win for defendants who had argued against litigation in states in which they are neither incorporated nor do business.

The New Jersey Appellate Division in McCarrell v. Hoffmann-La Roche found a lower court erred in its evidentiary rulings on science, causation and warnings. The Third Circuit U.S. Court of Appeals revived thousands of cases in In re: Fosamax Products Liability Litigation, finding that the trial court had improperly granted summary judgement on preemption grounds by misapplying the Supreme Court’s “clear evidence” standard in Wyeth v. Levine.

Because of these developments the judge has impaneled a group of experts to share their insights during a 90-minute educational webinar.

Join Judge Corodemus and her panel of experts on Sept. 18 when they will:

  • Review the case history of these seminal decisions.
  • Analyze the meaning and impact of the courts’ holdings.
  • Discuss critical issues now before many courts on specific personal jurisdiction and general jurisdiction, i.e. Daubert, Kemp and Frye.
  • Debate the future of these cases and whether they represent a change for the better.
  • Comment on whether class actions are changed forever.
  • Predict – as best they can – the real impact of these cases.
  • Answer your questions.

Speakers

Drugmakers Agree to $300M Settlement in MDL Over Hypertension Medication Benicar

Drugmakers Daiichi Sankyo and Forest Laboratories have agreed to a $300 million settlement in multidistrict litigation by users of hypertension drug Benicar who claimed they developed severe gastrointestinal side effects.

Attorneys placed the settlement on the record before U.S. District Judge Robert Kugler in Camden on Tuesday. The agreement would apply to about 2,000 cases from across the nation that were consolidated before Kugler, as well as another 100 cases pending in state Superior Court in Atlantic County. Kugler appointed former state Superior Court Judge Marina Corodemus, who served as a state mass tort judge, to oversee compliance with the agreement and dismissal of claims that fail to meet its conditions.

Read full article at the New Jersey Law Journal